Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection.
Angiotensin-Converting Enzyme 2
/ metabolism
Anti-Inflammatory Agents
/ therapeutic use
Antiviral Agents
/ therapeutic use
Drug Repositioning
Estradiol
/ therapeutic use
Estrogen Receptor Modulators
/ therapeutic use
Estrogens
/ metabolism
Female
Humans
Male
Raloxifene Hydrochloride
/ therapeutic use
SARS-CoV-2
/ drug effects
Sex Factors
COVID-19 Drug Treatment
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
25
01
2021
accepted:
25
07
2021
revised:
09
07
2021
pubmed:
19
8
2021
medline:
19
1
2022
entrez:
18
8
2021
Statut:
ppublish
Résumé
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.
Identifiants
pubmed: 34404919
doi: 10.1038/s41418-021-00844-6
pii: 10.1038/s41418-021-00844-6
pmc: PMC8370058
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antiviral Agents
0
Estrogen Receptor Modulators
0
Estrogens
0
Raloxifene Hydrochloride
4F86W47BR6
Estradiol
4TI98Z838E
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
156-166Subventions
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 101003551 - Exscalate4CoV
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 101003551
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : 12371675
Informations de copyright
© 2021. The Author(s).
Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
pubmed: 31986264
pmcid: 7159299
doi: 10.1016/S0140-6736(20)30183-5
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–9.
pubmed: 32031570
pmcid: 7042881
doi: 10.1001/jama.2020.1585
European Centre for Disease Prevention and Control. Outbreak of novel coronavirus disease 2019 (COVID-19): increased transmission globally—fifth update, 2 March 2020. Stockholm: ECDC; 2020.
Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet. 2003;361:1779–85.
pubmed: 12781537
pmcid: 7140172
doi: 10.1016/S0140-6736(03)13414-9
Who Mers-Cov Research Group. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans. PLoS Curr. 2013;5:ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
Romagnoli S, Peris A, De Gaudio AR, Geppetti P. SARS-CoV-2 and COVID-19: from the bench to the bedside. Physiol Rev. 2020;100:1455–66.
pubmed: 32496872
pmcid: 7347954
doi: 10.1152/physrev.00020.2020
Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)—possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis. 2013;17:e792–8.
pubmed: 23993766
pmcid: 7110699
doi: 10.1016/j.ijid.2013.07.002
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–99.
pubmed: 32187464
doi: 10.1056/NEJMoa2001282
Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948.
pubmed: 32201353
pmcid: 7156162
doi: 10.1016/j.ijantimicag.2020.105948
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci trends. 2020;14:69–71.
pubmed: 31996494
doi: 10.5582/bst.2020.01020
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6:1192-1198.
Sun D. Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer aditional benefit. AAPS J. 2020;22:77.
pubmed: 32458279
doi: 10.1208/s12248-020-00459-8
Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother. 2020;75:2977–80.
pubmed: 32607555
doi: 10.1093/jac/dkaa239
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC-C, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020;27:ciaa478.
Jomah S, Asdaq SMB, Al-Yamani MJ. Clinical efficacy of antivirals against novel coronavirus (COVID-19): a review. J Infect Public Health. 2020;13:1187–95.
pubmed: 32773212
pmcid: 7396961
doi: 10.1016/j.jiph.2020.07.013
Vanhaelen Q, Mamoshina P, Aliper AM, Artemov A, Lezhnina K, Ozerov I, et al. Design of efficient computational workflows for in silico drug repurposing. Drug Discov today. 2017;22:210–22.
pubmed: 27693712
doi: 10.1016/j.drudis.2016.09.019
Karaman B, Sippl W. Computational drug repurposing: current trends. Curr Med Chem. 2019;26:5389–409.
pubmed: 29848268
doi: 10.2174/0929867325666180530100332
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.
pubmed: 30310233
doi: 10.1038/nrd.2018.168
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–7.
pubmed: 12746549
doi: 10.1126/science.1085658
Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem Pharm. 2021;183:114296.
pubmed: 33191206
doi: 10.1016/j.bcp.2020.114296
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92:814–8.
pubmed: 32253759
doi: 10.1002/jmv.25801
Wu C, Chen X, Cai Y, Xia JA, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–43.
pubmed: 32167524
doi: 10.1001/jamainternmed.2020.0994
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
pubmed: 32217556
pmcid: 7190011
doi: 10.1136/bmj.m1091
Dudley JP, Lee NT. Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea. Clin Infect Dis. 2020;71:863–5.
pubmed: 32232322
doi: 10.1093/cid/ciaa354
Bartz D, Chitnis T, Kaiser UB, Rich-Edwards JW, Rexrode KM, Pennell PB, et al. Clinical advances in sex- and gender-informed medicine to improve the health of all: a review. JAMA Intern Med. 2020;180:574–83.
pubmed: 32040165
doi: 10.1001/jamainternmed.2019.7194
Strope JD, Chau CH, Figg WD. Are sex discordant outcomes in COVID-19 related to sex hormones? Semin Oncol. 2020;47:335–40.
Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34:339–43.
pubmed: 32253888
Bischof E, Wolfe J, Klein SL. Clinical trials for COVID-19 should include sex as a variable. J Clin Investig. 2020;130:3350–2.
pubmed: 32392184
pmcid: 7324163
doi: 10.1172/JCI139306
Lange SJ, Ritchey MD, Goodman AB, Dias T, Twentyman E, Fuld J, et al. Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions—United States, January-May 2020. MMWR. 2020;69:795–800.
pubmed: 32584802
pmcid: 7316316
Bianchi VE. The anti-inflammatory effects of testosterone. J Endocr Soc. 2018;3:91–107.
pubmed: 30582096
pmcid: 6299269
doi: 10.1210/js.2018-00186
La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. Int J Mol Sci. 2020;21:2948.
Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J, et al. A multi-hospital study in Wuhan, China: protective effects of non-menopause and female hormones on SARS-CoV-2 infection. 2020. https://doi.org/10.1101/2020.03.26.20043943 .
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.
pubmed: 14647384
pmcid: 7095016
doi: 10.1038/nature02145
Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5:562–9.
pubmed: 32094589
doi: 10.1038/s41564-020-0688-y
Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020;318:L1280–1.
pubmed: 32432918
pmcid: 7276982
doi: 10.1152/ajplung.00153.2020
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. 2020. https://doi.org/10.1101/2020.01.26.919985 .
Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci. 2020;21:3474.
Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198:4046–53.
pubmed: 28373583
doi: 10.4049/jimmunol.1601896
Vermillion MS, Ursin RL, Attreed SE, Klein SL. Estriol reduces pulmonary immune cell recruitment and inflammation to protect female mice from severe influenza. Endocrinology. 2018;159:3306–20.
pubmed: 30032246
pmcid: 6109301
doi: 10.1210/en.2018-00486
Magri A, Barbaglia MN, Foglia CZ, Boccato E, Burlone ME, Cole S, et al. 17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle. Liver Int. 2017;37:669–77.
pubmed: 27885811
doi: 10.1111/liv.13303
Fantozzi ET, Breithaupt-Faloppa AC, Ricardo-da-Silva FY, Rodrigues-Garbin S, Romero DC, da Silva Rodrigues A, et al. Estradiol mediates the long-lasting lung inflammation induced by intestinal ischemia and reperfusion. J Surg Res. 2018;221:1–7.
pubmed: 29229114
doi: 10.1016/j.jss.2017.07.038
Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294:63–69.
pubmed: 25682174
pmcid: 4380804
doi: 10.1016/j.cellimm.2015.01.018
Lahm T, Crisostomo PR, Markel TA, Wang M, Weil BR, Novotny NM, et al. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med. 2008;36:2174–83.
pubmed: 18552699
doi: 10.1097/CCM.0b013e31817d1a92
Breithaupt-Faloppa AC, Correia CDJ, Prado CMX, Stilhano RS, Ureshino RP, Moreira LFP. 17
Martinkovich S, Shah D, Planey SL, Arnott JA. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Interv Aging. 2014;9:1437–52.
pubmed: 25210448
pmcid: 4154886
Marin FBM. Clinical pharmacology of selective estrogen receptor modulators (SERMs), 2006. In: Cano Sanchez A, Calaf I Alsina J, Dueñas-Díez JL, editors. Selective estrogen receptor modulators—a new brand of multitarget drugs. Chapter 2. Heidelberg: Springer-Verlag Berlin Heidelberg; 2006.
Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol. 2005;23:1644–55.
pubmed: 15755972
doi: 10.1200/JCO.2005.11.005
Rosano C, Stec-Martyna E, Lappano R, Maggiolini M. Structure-based approach for the discovery of novel selective estrogen receptor modulators. Curr Med Chem. 2011;18:1188–94.
pubmed: 21291367
doi: 10.2174/092986711795029645
Beato M. Gene regulation by steroid hormones. Cell. 1989;56:335–44.
pubmed: 2644044
doi: 10.1016/0092-8674(89)90237-7
Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 1989;59:477–87.
pubmed: 2805068
doi: 10.1016/0092-8674(89)90031-7
Powell E, Xu W. Intermolecular interactions identify ligand-selective activity of estrogen receptor alpha/beta dimers. Proc Natl Acad Sci USA. 2008;105:19012–7.
pubmed: 19022902
pmcid: 2596243
doi: 10.1073/pnas.0807274105
Lasso G, Mayer SV, Winkelmann ER, Chu T, Elliot O, Patino-Galindo JA, et al. A structure-informed atlas of human-virus interactions. Cell. 2019;178:1526–41.e1516.
pubmed: 31474372
pmcid: 6736651
doi: 10.1016/j.cell.2019.08.005
Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2015;5:190ra179.
Montoya MC, Krysan DJ. Repurposing estrogen receptor antagonists for the treatment of infectious disease. mBio. 2018;9:e02272–18.
pubmed: 30563895
pmcid: 6299222
doi: 10.1128/mBio.02272-18
Laurence J, Cooke H, Sikder SK. Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1. Blood. 1990;75:696–703.
pubmed: 2297571
doi: 10.1182/blood.V75.3.696.696
Watashi K, Inoue D, Hijikata M, Goto K, Aly HH, Shimotohno K. Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem. 2007;282:32765–72.
pubmed: 17704057
doi: 10.1074/jbc.M704418200
Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58:4885–93.
pubmed: 24841273
pmcid: 4136000
doi: 10.1128/AAC.03036-14
de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58:4875–84.
pubmed: 24841269
pmcid: 4136071
doi: 10.1128/AAC.03011-14
Cong Y, Hart BJ, Gross R, Zhou H, Frieman M, Bollinger L, et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS ONE. 2018;13:e0194868.
pubmed: 29566060
pmcid: 5864050
doi: 10.1371/journal.pone.0194868
Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature. 2016;535:169–72.
pubmed: 27362232
pmcid: 4947387
doi: 10.1038/nature18615
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14.
pubmed: 32194980
pmcid: 7073332
doi: 10.1038/s41421-020-0153-3
Montopoli M, Zorzi M, Cocetta V, Prayer-Galetti T, Guzzinati S, Bovo E, et al. Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy. Ann Oncol. 2021;32:676–7.
pubmed: 33524477
doi: 10.1016/j.annonc.2021.01.069
Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat Struct Biol. 2003;10:980.
pubmed: 14634627
doi: 10.1038/nsb1203-980
Hernández E, Valera R, Alonzo E, Bajares-Lilue M, Carlini R, Capriles F, et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 2003;63:2269–74.
pubmed: 12753317
doi: 10.1046/j.1523-1755.2003.00005.x
Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 2005;591:247–63.
pubmed: 16083919
doi: 10.1016/j.mrfmmm.2005.02.028
Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–51.
pubmed: 9600478
doi: 10.1001/jama.279.18.1445
Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab. 2004;89:6097–9.
pubmed: 15579764
doi: 10.1210/jc.2004-0795
Dickler MN, Norton L. The MORE trial: multiple outcomes for raloxifene evaluation–breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci. 2001;949:134–42.
pubmed: 11795345
doi: 10.1111/j.1749-6632.2001.tb04011.x
Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.
pubmed: 16837676
doi: 10.1056/NEJMoa062462
Vogel VG. The NSABP study of tamoxifen and raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009;9:51–60.
pubmed: 19105706
pmcid: 2785111
doi: 10.1586/14737140.9.1.51
Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 2001;16:2118–25.
pubmed: 11697809
doi: 10.1359/jbmr.2001.16.11.2118
Duschek EJ, Gooren LJ, Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol. 2004;150:539–46.
pubmed: 15080785
doi: 10.1530/eje.0.1500539
Francucci CM, Daniele P, Iori N, Camilletti A, Massi F, Boscaro M. Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. J Endocrinol Investig. 2005;28:623–31.
doi: 10.1007/BF03347261
Ellis AJ, Hendrick VM, Williams R, Komm BS. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf. 2015;14:921–34.
pubmed: 25936229
doi: 10.1517/14740338.2015.1014799
An K-C. Selective estrogen receptor modulators. Asian Spine J. 2016;10:787–91.
pubmed: 27559463
pmcid: 4995266
doi: 10.4184/asj.2016.10.4.787
Yoon Y-S, Jang Y, Hoenen T, Shin H, Lee Y, Kim M. Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB Rep. 2020;53:166–71.
pubmed: 31964466
pmcid: 7118351
doi: 10.5483/BMBRep.2020.53.3.175
Kouznetsova J, Sun W, Martínez-Romero C, Tawa G, Shinn P, Chen CZ, et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014;3:e84.
pubmed: 26038505
pmcid: 4317638
doi: 10.1038/emi.2014.88
Takeda M, Ikeda M, Mori K, Yano M, Ariumi Y, Dansako H, et al. Raloxifene inhibits hepatitis C virus infection and replication. FEBS Open Bio. 2012;2:279–83.
pubmed: 23650611
pmcid: 3642163
doi: 10.1016/j.fob.2012.08.003
Murakami Y, Fukasawa M, Kaneko Y, Suzuki T, Wakita T, Fukazawa H. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microbes Infect. 2013;15:45–55.
pubmed: 23103222
doi: 10.1016/j.micinf.2012.10.003
Lamontagne J, Mills C, Mao R, Goddard C, Cai D, Guo H, et al. Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system. Antivir Res. 2013;98:19–26.
pubmed: 23415884
doi: 10.1016/j.antiviral.2013.02.001
Eyre NS, Kirby EN, Anfiteatro DR, Bracho G, Russo AG, White PA, et al. Identification of estrogen receptor modulators as inhibitors of flavivirus infection. Antimicrobial Agents Chemother. 2020;64:e00289–20.
doi: 10.1128/AAC.00289-20
Peretz J, Pekosz A, Lane AP, Klein SL. Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors. Am J Physiol Lung Cell Mol Physiol. 2016;310:L415–425.
pubmed: 26684252
doi: 10.1152/ajplung.00398.2015
Furusyo N, Ogawa E, Sudoh M, Murata M, Ihara T, Hayashi T, et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J Hepatol. 2012;57:1186–92.
pubmed: 22889955
doi: 10.1016/j.jhep.2012.08.003
Hong S, Chang J, Jeong K, Lee W. Raloxifene as a treatment option for viral infections. J Microbiol. 2021;59:124–31.
pubmed: 33527314
pmcid: 7849956
doi: 10.1007/s12275-021-0617-7
Jarvis MA, Hansen FA, Rosenke K, Haddock E, Rollinson C, Rule S, et al. Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system. Antivir Ther. 2020;25:223–31.
pubmed: 32744511
doi: 10.3851/IMP3368
Aditya N, Ravi PR, Vats R. Lipid nanoparticles for oral delivery of raloxifene hydrochloride: preparation, characterization, biodistribution and pharmacokinetic studies. Conference Paper. AAPS Annual Meeting and Exposition; 2012.
Zahori G, Lu L, Chunyan L, Yongli G. Progresses in clinical studies on antiviral therapies for COVID-19—experience and lessons in design of clinical trials. Pediatr Investig. 2020;4:263–74.
doi: 10.1002/ped4.12227
Indari O, Jakhmola, Manivannan E, Jha EH. An update on antiviral therapy against SARS-CoV-2: how far have we come? Front Pharm. 2021;12:632–77.
doi: 10.3389/fphar.2021.632677
Réa-Neto A, Bernardelli RS, Câmara BMD, Reese FB, Queiroga MVO, Oliveira MC. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. Sci Rep. 2021;11:9023.
pubmed: 33907251
pmcid: 8079411
doi: 10.1038/s41598-021-88509-9
Wong CKH, Wan EYF, Luo S, Ding Y, Lau EHY, Ling P, et al. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: a propensity-score analysis. EClinical Med. 2021;32:100743.
doi: 10.1016/j.eclinm.2021.100743
Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64:e01061.
pubmed: 32661006
pmcid: 7449227
doi: 10.1128/AAC.01061-20
Feld JJ, Kandel C, Biondi MJ, Kozak RA, Zahoor MA, Lemieux C, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021;9:498–510.
pubmed: 33556319
pmcid: 7906707
doi: 10.1016/S2213-2600(20)30566-X
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9:196–206.
pubmed: 33189161
doi: 10.1016/S2213-2600(20)30511-7
Rodriguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Macho O, López GF, et al. Observational study of azithromycin in hospitalized patients with COVID-19. PLoS ONE. 2020;15:e0238681.
pubmed: 32881982
pmcid: 7470304
doi: 10.1371/journal.pone.0238681
Pandey A, Nikam AN, Shreya AB, Mutalik SP, Gopalan D, Kulkarni S, et al. Potential therapeutic targets for combating SARS-CoV-2: drug repurposing, clinical trials and recent advancements. Life Sci. 2020;256:117883.
pubmed: 32497632
pmcid: 7263255
doi: 10.1016/j.lfs.2020.117883
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503–16.
pubmed: 33631066
doi: 10.1056/NEJMoa2028700
Palanques-Pastor T, López-Briz E, Poveda, Andrés JL. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19. Eur J Hosp Pharm. 2020;27:297–8.
pubmed: 32499314
pmcid: 7447248
doi: 10.1136/ejhpharm-2020-002322
Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:522–32.
pubmed: 33676590
pmcid: 8078879
doi: 10.1016/S2213-2600(21)00099-0
CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9:295–304.
doi: 10.1016/S2213-2600(20)30556-7
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693ȓ704.
Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The efficacy of famotidine in improvement of outcomes in hospitalized COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:848.
pubmed: 33050945
pmcid: 7552598
doi: 10.1186/s13063-020-04773-6
Mansour E, Bueno FF, de Lima-Júnior JC, Palma A, Monfort-Pires M, Bombassaro B, et al. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials. 2021;22:71.
pubmed: 33472675
pmcid: 7816150
doi: 10.1186/s13063-021-05027-9
Chen J, Xia L, Liu L, Xu Q, Ling Y, Huang D, et al. Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. OFID. 2021;7:ofaa241.
doi: 10.1093/ofid/ofaa241
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146:137–46.e3.
pubmed: 32470486
pmcid: 7250105
doi: 10.1016/j.jaci.2020.05.019
Garcia PJ, Mundaca H, Ugarte-Gil C, Leon P, Malaga G, Chaccour C, et al. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Trials. 2021;22:262.
pubmed: 33836826
pmcid: 8033091
doi: 10.1186/s13063-021-05236-2
Cooper L, Schafer A, Li Y, Cheng H, Medegan Fagla B, Shen Z, et al. Screening and reverse-engineering of estrogen receptor ligands as potent pan-filovirus inhibitors. J Med Chem. 2020;63:11085–99.
pubmed: 32886512
pmcid: 7904233
doi: 10.1021/acs.jmedchem.0c01001
Liu Q, Xia S, Sun Z, Wang Q, Du L, Lu L. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015;59:742–4.
pubmed: 25331705
doi: 10.1128/AAC.03977-14
Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, et al. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antivir Res. 2016;125:1–7.
pubmed: 26585243
doi: 10.1016/j.antiviral.2015.11.003
Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, et al. Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J Virol. 2020;94:e01218.
pubmed: 32817221
pmcid: 7565640
doi: 10.1128/JVI.01218-20
Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64:e00819–20.
pubmed: 32366720
pmcid: 7318052
doi: 10.1128/AAC.00819-20